Combining GHK-Cu and Tirzepatide: the Decision Explained

What GHK-Cu actually is, and why it sits in a regulatory grey zone

GHK-Cu (glycine-histidine-lysine copper) is a tripeptide that occurs naturally in human blood plasma and has been the subject of laboratory and animal research exploring wound healing, collagen production and anti-inflammatory signalling. It appears in some cosmetic serums and, increasingly, in injectable peptide products sold through grey-market wellness channels. That last point is important: in the UK, injectable GHK-Cu formulations have no marketing authorisation from the MHRA. That means no standardised manufacturing controls, no confirmed purity, no approved dosing schedule, and no formal pharmacovigilance network to capture problems if they arise.

This is a meaningful distinction from tirzepatide, which holds a full UK licence, is manufactured to pharmaceutical-grade standards, and carries a Black Triangle (▼) designation, meaning the MHRA actively collects safety data on it. When you place an unlicensed injectable compound alongside a tightly monitored prescription medicine, you introduce variables that no trial has characterised. Your prescriber cannot assess an interaction they cannot see documented, which is why disclosure is the first step, not an optional one.

If you are curious about how tirzepatide's own mechanism works, the tirzepatide overview on this site covers the dual-receptor science in plain language.

The real decision: what changes when you add something unregulated to a POM regimen

The practical question most people asking this are trying to answer is: will GHK-Cu undermine my tirzepatide, add something useful, or cause harm? Honest answer: nobody has tested it, so nobody can tell you with confidence. What we can reason through is the risk framework.

Tirzepatide slows gastric emptying, which affects the absorption timing of anything taken orally. GHK-Cu used topically (in a serum, for instance) is unlikely to reach systemic concentrations that would interfere with tirzepatide's mechanism. Injectable GHK-Cu is a different matter, any injectable compound carries infection risk at the site, and if the source is not pharmaceutical-grade, contamination risk compounds that. The MHRA has warned publicly about unlicensed injectable products circulating through social-media channels, noting that content and sterility cannot be assumed. That warning extends well beyond weight-loss medicines.

There is also a straightforward monitoring point worth making: tirzepatide is associated with gastrointestinal side effects, particularly in the early weeks of treatment or after a dose increase. If you introduce a second compound at the same time and experience nausea, fatigue or injection-site reactions, attributing the cause becomes harder. Keeping changes separated by several weeks, if your prescriber agrees any change is appropriate at all, makes it easier to identify what is doing what. That is a checking habit you can apply in under a minute: before adding anything new, look at when your last tirzepatide dose adjustment was, and whether you have had a stable few weeks with no new symptoms.

Some people researching peptide combinations also look at compounds like MOTS-c and tirzepatide or tirzepatide and HGH, the same framework applies to all of them: a research gap is not reassurance.

What your prescriber needs to know before you decide

Disclosing everything you take is not bureaucratic, it protects you. A GPhC-registered prescriber reviewing your tirzepatide treatment cannot advise accurately if they do not have the full picture. That includes supplements, OTC products, cosmetic injectables and anything in the unlicensed peptide category. The Mounjaro information page sets out what the prescribing assessment covers, and the FAQs page addresses common questions about what to disclose during a review.

A few things specifically worth raising with your prescriber: the source of your GHK-Cu product, whether it is topical or injectable, the frequency of use, and any symptoms you have noticed since starting it. If you are using HRT alongside tirzepatide, the Mounjaro and HRT page covers the separate absorption considerations the NHS flags for that combination, relevant background if you are juggling multiple products. The NHS medicines page for tirzepatide details the known interaction profile for the medicine itself, including the oral contraceptive absorption point that applies in the first weeks of treatment and after each dose step up.

On cost: if tirzepatide's private price is part of your thinking as you decide whether to add other compounds to your regimen, a clear breakdown of what goes into UK private treatment pricing is on the Mounjaro price comparison page.

The short version of this decision: the absence of published interaction data for GHK-Cu and tirzepatide means the responsible path is to raise it with your prescriber before proceeding, not after. If you would like that conversation with a real clinician, you can speak to our prescribers as part of a free consultation.